This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record.
1. Trial at a Glance
LOOP was a randomized, parallel-group clinical trial evaluating an implantable loop recorder, the Medtronic Reveal LINQ(TM), in a population with conditions including atrial fibrillation, stroke, hypertension, and diabetes. The registry lists 6000 enrolled participants and a primary endpoint based on time to the first adjudicated stroke or systemic arterial embolism.
| Feature | LOOP |
|---|---|
| Study acronym | LOOP |
| ClinicalTrials.gov identifier | NCT02036450 |
| Title | Atrial Fibrillation Detected by Continuous ECG Monitoring |
| Status | Completed |
| Phase | NA |
| Enrollment | 6000 |
| Allocation | Randomized |
| Design model | Parallel |
| Masking | None |
| Primary purpose | Treatment |
| Number of arms | 2 |
| Lead sponsor | Rigshospitalet, Denmark |
| Sponsor type | OTHER |
2. Clinical Question
The registry identifies atrial fibrillation, stroke, hypertension, and diabetes among the conditions studied and identifies an implantable loop recorder as the intervention. The primary statistical question is framed around whether the randomized comparison affects the time until the first adjudicated stroke or systemic arterial embolism.
Population
The registry lists atrial fibrillation, stroke, hypertension, and diabetes among the study conditions. The total enrollment was 6000 participants.
Intervention
Implantable loop recorder (Medtronic Reveal LINQ(TM)), classified as a device intervention.
Comparator
The study has 2 randomized arms, but the registry information presented here does not specify the comparator intervention.
Primary question
How does the randomized comparison relate to time to the first adjudicated stroke or systemic arterial embolism?
3. Trial Design
The randomized parallel-group structure is important statistically because the treatment comparison is established at randomization rather than by comparing observationally selected groups. The absence of masking means that treatment assignment was not masked, which is a separate design characteristic from randomization.
4. Trial Timeline
Trial start
The LOOP trial began in January 2014.
Primary endpoint period
The registry specifies that the primary endpoint was to be evaluated at the completion of the event-driven trial, expected at 4 years.
Primary completion
The registry lists February 2020 as the primary completion date.
5. Endpoints
The primary endpoint is a time-to-event composite endpoint. The registry defines it as time to the first of either adjudicated stroke or adjudicated systemic arterial embolism.
| Endpoint | Registry definition | Time frame |
|---|---|---|
| Primary endpoint | Time to the first of one of the components of the combined primary endpoint: adjudicated stroke, or adjudicated systemic arterial embolism. | At the completion of the event-driven trial, expected 4 years. |
Why the endpoint is time-to-first-event
The endpoint is not simply the proportion of participants who ever experienced stroke or systemic arterial embolism. It is defined by time to the first event. That distinction determines the appropriate statistical framework: participants contribute follow-up over time, and participants who have not experienced the endpoint by the end of their available observation can be censored rather than treated as if they had no possibility of a future event.
Why the composite endpoint matters
The primary endpoint combines two clinically defined event types. A participant enters the primary endpoint when the first qualifying component occurs. The composite therefore creates a single time-to-event outcome while retaining both adjudicated stroke and adjudicated systemic arterial embolism as components of the endpoint.
6. Planned Analysis
The registry describes an event-driven primary endpoint evaluated at completion of the trial, expected at 4 years. No formal statistical analyses are posted in the ClinicalTrials.gov record.
How a time-to-event endpoint of this type is typically analyzed
For a randomized two-arm trial with a primary endpoint defined as time to first adjudicated stroke or systemic arterial embolism, a standard analysis would generally estimate the event-time distribution with the Kaplan-Meier method and compare randomized groups with a log-rank test. A Cox proportional-hazards model is commonly used to estimate a hazard ratio and its confidence interval.
The Kaplan-Meier estimator uses the number of participants at risk immediately before each event time and the number experiencing the event at that time. Participants who are censored contribute information up to their censoring time.
A formal Cox analysis would estimate a relative instantaneous event rate between randomized groups. If the estimated hazard ratio were below 1, the usual interpretation would be a lower estimated hazard in the intervention group over the analyzed period. The hazard ratio would not, by itself, represent an absolute reduction in the probability of stroke or systemic arterial embolism.
7. Statistical Methodology
Randomization and causal comparison
Randomization is the central statistical feature of the LOOP design. With 6000 participants assigned across 2 arms, random allocation is intended to make treatment assignment independent of participants' baseline characteristics in expectation. This provides the basis for comparing subsequent time-to-event outcomes between the randomized groups.
The absence of masking should be interpreted separately. A randomized trial can retain the statistical benefits of randomization even when treatment assignment is not masked, although knowledge of assignment can affect aspects of treatment delivery, monitoring, behavior, or outcome assessment depending on the endpoint.
Kaplan-Meier estimation
Kaplan-Meier estimation is particularly appropriate for an endpoint that records time until the first event. It uses the available follow-up from each participant without requiring every participant to be observed until an event occurs.
For this trial's primary endpoint, the survival function can be understood as the probability of remaining free of adjudicated stroke or systemic arterial embolism through a given time, subject to the assumptions of the censoring mechanism.
Log-rank comparison
The log-rank test is a standard method for comparing time-to-event distributions between randomized groups. Rather than comparing only a single time point, it incorporates the ordering of observed events throughout follow-up.
For an event-driven trial, this approach is especially useful because the amount of statistical information increases as qualifying events accumulate. The registry's expectation of a 4-year event-driven endpoint therefore describes a follow-up framework in which the primary analysis depends on the accumulation of events rather than solely on a fixed calendar date.
Cox proportional-hazards model
A Cox model provides a way to express the treatment comparison as a hazard ratio. The model focuses on the relative instantaneous rate of experiencing the primary endpoint among participants who remain at risk.
A hazard ratio is a relative time-to-event measure. It is not the same as a relative risk, an absolute risk difference, a probability of remaining event-free, or the percentage of participants who benefit.
Adjudication
The primary endpoint specifically uses adjudicated stroke and systemic arterial embolism. Adjudication is important because the endpoint is defined not simply by an unreviewed event report, but by an endpoint classification process. The statistical analysis should therefore preserve the registry's endpoint definition rather than substituting a broader or differently defined stroke outcome.
8. Statistical Methods Explained
Why use time to the first event instead of only counting events?
Participants may have different amounts of follow-up, and an event occurring early carries different information from an event occurring much later. A time-to-event analysis uses both the occurrence of the endpoint and when it occurred. It also allows participants who have not yet experienced the endpoint to contribute follow-up through censoring.
What does a Kaplan-Meier curve represent?
A Kaplan-Meier curve estimates the probability of remaining free of the primary endpoint over time. For LOOP, that endpoint-free state corresponds to having experienced neither adjudicated stroke nor adjudicated systemic arterial embolism up to the relevant time.
What would a hazard ratio represent?
A hazard ratio would summarize the relative instantaneous rate of the primary endpoint between the randomized groups under a Cox model. An HR of 1 would indicate equal modeled hazards; an HR below 1 would indicate a lower estimated hazard in the intervention group; and an HR above 1 would indicate a higher estimated hazard.
Why does censoring matter?
Censoring occurs when a participant's event-free follow-up ends before the primary endpoint is observed. Kaplan-Meier and Cox analyses can incorporate such observations, but their interpretation depends on assumptions about the relationship between censoring and the underlying event process. Censoring is therefore a central part of time-to-event analysis rather than a simple removal of participants from the analysis.
Why does the composite endpoint require careful interpretation?
A composite endpoint combines adjudicated stroke and adjudicated systemic arterial embolism into one primary time-to-first-event outcome. The overall result of the composite would reflect whichever component occurs first. Interpretation should therefore distinguish the composite endpoint from either component considered alone.
Why does an event-driven design matter?
In an event-driven trial, the statistical information for a time-to-event comparison is closely related to the number of observed endpoint events. A calendar duration such as 4 years describes the expected timing of trial completion, but the amount of information ultimately available depends on the accumulation of qualifying events and the follow-up contributed by participants.
9. Analysis Population and Missing Data Considerations
The registry information presented here identifies randomization, 6000 enrollment, and a two-arm parallel design but does not provide separate analysis-population definitions, missing-data procedures, or imputation methods.
Randomized population
Randomization establishes the primary comparison between the 2 study arms and is the foundation for an intention-to-treat efficacy analysis.
Follow-up
The primary endpoint is explicitly time-to-first-event, so the amount and timing of follow-up are statistically important.
Censoring
Participants without an observed primary endpoint by the end of available follow-up would ordinarily contribute censored time in a survival analysis.
Missing-data strategy
The ClinicalTrials.gov record does not report a specific missing-data or imputation strategy for the primary endpoint.
10. Non-Inferiority, Factorial Design, and Bayesian Methods
The registry information presented for LOOP describes a randomized, parallel-group design with 2 arms. It does not identify a non-inferiority margin, factorial design, or Bayesian primary analysis.
| Design topic | Registry information | Statistical implication |
|---|---|---|
| Non-inferiority margin | Not reported | No non-inferiority margin can be specified from the registry information. |
| Factorial design | Not reported | The design is identified as parallel rather than factorial. |
| Bayesian methods | Not reported | No Bayesian primary analysis is identified. |
| Interim analysis | Not reported | No interim-testing procedure can be described from the registry information. |
| Multiplicity | Not reported | No multiplicity-adjustment procedure is identified. |
| Missing-data / imputation | Not reported | No specific imputation procedure is identified for the primary endpoint. |
| Stratification | Not reported | No randomization strata are identified in the registry information presented here. |
11. Limitations
- No posted statistical estimates: the ClinicalTrials.gov record does not report numerical results for the primary endpoint in the record summarized here.
- No event counts: the registry information does not provide the number of adjudicated strokes, systemic arterial embolisms, or total primary-endpoint events.
- No effect estimate: there is no posted hazard ratio, risk estimate, or other treatment-effect estimate for the primary endpoint in the registry record summarized here.
- No confidence interval: uncertainty around a treatment-effect estimate cannot be characterized numerically without a reported estimate and interval.
- No p-value: the registry does not report a formal statistical test result for the primary endpoint in the record summarized here.
- Comparator details: the registry information presented here identifies 2 randomized arms but does not specify the comparator intervention.
- Analysis specification: the record does not provide the detailed statistical-analysis population, censoring rules, stratification factors, multiplicity procedure, or missing-data strategy needed to reconstruct a complete prespecified analysis plan.
- Composite endpoint: interpretation of a future statistical result would require attention to both components of the combined endpoint rather than treating the composite as a single undifferentiated clinical event.
12. Why This Trial Matters Statistically
LOOP is a useful statistical teaching case because the central outcome is a clinically meaningful time-to-first-event composite endpoint evaluated in a randomized parallel-group design. The trial illustrates why the choice of endpoint determines the statistical framework: a simple comparison of percentages would discard information about when events occurred and how long participants remained event-free.
| Concept | How it appears in LOOP |
|---|---|
| Randomization | Participants were randomly allocated in a two-arm study. |
| Parallel design | The registry identifies a parallel design model. |
| Time-to-event analysis | The primary endpoint is time to the first qualifying event. |
| Composite endpoint | Adjudicated stroke and adjudicated systemic arterial embolism form the combined primary endpoint. |
| Adjudication | Both primary-endpoint components are explicitly described as adjudicated. |
| Event-driven design | The primary endpoint was to be assessed at completion of the event-driven trial, expected 4 years. |
| Kaplan-Meier estimation | A standard method for describing time to the first event and event-free survival. |
| Log-rank testing | A standard method for comparing time-to-event distributions between randomized groups. |
| Cox regression | A standard model for expressing the relative event rate as a hazard ratio. |
| Censoring | Participants without an observed event can contribute event-free follow-up until censoring. |
| Absolute versus relative effects | Time-specific event-free probabilities and hazard ratios answer different statistical questions. |
13. Interpreting a Future Hazard Ratio
If a future analysis reported an OS-like time-to-event hazard ratio of 0.70 for the primary endpoint, the model-based interpretation would be that the estimated instantaneous rate of adjudicated stroke or systemic arterial embolism was approximately 30% lower in the intervention group than in the comparator group, under the assumptions of the model.
That interpretation would not mean that 30% of participants avoided the endpoint, that the absolute event probability was reduced by 30 percentage points, or that every participant experienced the same reduction.
A confidence interval around a hazard ratio would describe statistical uncertainty around the estimated relative effect under the specified model and sampling framework. A narrow interval would indicate greater statistical precision than a wide interval, but neither would describe the range of effects experienced by individual participants.
For a time-to-event endpoint, absolute event-free probabilities at clinically meaningful time points can complement the hazard ratio. Absolute measures help show the difference in predicted event-free experience, while the hazard ratio summarizes a relative rate comparison.
14. Proportional-Hazards Assumption
A Cox hazard ratio is often interpreted as a relative hazard that is reasonably stable over time. That interpretation depends on the proportional-hazards assumption. If the relative hazards change substantially during follow-up, a single hazard ratio may compress important temporal information.
For a primary endpoint with expected follow-up of 4 years, a complete statistical report would therefore benefit from examining the estimated event-free curves as well as the hazard ratio. The curve provides information about when separation occurs and whether the relative treatment effect appears reasonably consistent over time.
15. Composite Endpoint Interpretation
The LOOP primary endpoint is defined as time to the first of two adjudicated events: stroke or systemic arterial embolism. This construction has several statistical consequences.
First qualifying event
Only the first component event determines when a participant reaches the combined primary endpoint.
Two component types
Stroke and systemic arterial embolism are distinct clinical outcomes even though they contribute to the same statistical endpoint.
Composite interpretation
A treatment comparison for the composite should not automatically be interpreted as showing the same effect on each individual component.
Component analysis
Understanding the composition of the endpoint would require separate event counts and analyses for the individual components.
The registry record summarized here does not report those component-level results. Consequently, the statistical interpretation available from the registry is centered on the prespecified combined endpoint definition.
16. Clinical Interpretation vs Statistical Interpretation
Statistical interpretation
The primary endpoint is a randomized time-to-event comparison. Appropriate analysis would account for the timing of adjudicated events and the censored follow-up contributed by participants who remain event-free.
Clinical interpretation
The endpoint is intended to capture clinically important thromboembolic outcomes through adjudicated stroke or systemic arterial embolism. The clinical meaning of any future statistical estimate depends on both its magnitude and its precision.
17. What Is Known and What Is Not Reported in the Registry
| Item | Registry record |
|---|---|
| Trial status | Completed |
| Enrollment | 6000 |
| Study arms | 2 |
| Allocation | Randomized |
| Design model | Parallel |
| Masking | None |
| Primary purpose | Treatment |
| Intervention | Implantable loop recorder (Medtronic Reveal LINQ(TM)) |
| Primary endpoint | Time to adjudicated stroke or systemic arterial embolism |
| Primary endpoint time frame | At completion of the event-driven trial, expected 4 years |
| Primary endpoint event counts | Not reported in the registry record summarized here |
| Hazard ratio | Not reported in the registry record summarized here |
| Confidence interval | Not reported in the registry record summarized here |
| P-value | Not reported in the registry record summarized here |
| Secondary endpoint results | Not reported in the registry record summarized here |
| Serious adverse events by arm | Not reported in the registry record summarized here |
18. Sources
- ClinicalTrials.gov: LOOP — NCT02036450.
Continue through the Clinical Biostats clinical-trial library
Clinical trial pages connect study design, endpoints, survival analysis, and statistical interpretation in a consistent educational format.
19. Record Summary
LOOP is a randomized, parallel-group trial enrolling 6000 participants with an implantable loop recorder identified as the intervention. Its primary endpoint is a clinically defined time-to-first-event composite of adjudicated stroke or adjudicated systemic arterial embolism, evaluated at completion of an event-driven trial expected at 4 years. The central statistical framework is therefore a survival-analysis problem: the comparison must account for both whether the primary endpoint occurs and when it occurs.
The registry identifies the major design features needed to understand that framework—randomization, 2 arms, parallel allocation, no masking, and an event-driven primary endpoint—but does not post numerical primary-endpoint results or the detailed analysis specifications needed to reconstruct them. For statistical education, the trial provides a clear example of how randomization, adjudication, censoring, Kaplan-Meier estimation, log-rank comparison, Cox modeling, and composite endpoint interpretation fit together in a clinical trial.